548 related articles for article (PubMed ID: 36644237)
1. A randomized, double-blind, placebo-controlled phase IIa trial of efruxifermin for patients with compensated NASH cirrhosis.
Harrison SA; Ruane PJ; Freilich B; Neff G; Patil R; Behling C; Hu C; Shringarpure R; de Temple B; Fong E; Tillman EJ; Rolph T; Cheng A; Yale K
JHEP Rep; 2023 Jan; 5(1):100563. PubMed ID: 36644237
[TBL] [Abstract][Full Text] [Related]
2. Safety and efficacy of once-weekly efruxifermin versus placebo in non-alcoholic steatohepatitis (HARMONY): a multicentre, randomised, double-blind, placebo-controlled, phase 2b trial.
Harrison SA; Frias JP; Neff G; Abrams GA; Lucas KJ; Sanchez W; Gogia S; Sheikh MY; Behling C; Bedossa P; Shao L; Chan D; Fong E; de Temple B; Shringarpure R; Tillman EJ; Rolph T; Cheng A; Yale K;
Lancet Gastroenterol Hepatol; 2023 Dec; 8(12):1080-1093. PubMed ID: 37802088
[TBL] [Abstract][Full Text] [Related]
3. Effect of pegbelfermin on NASH and fibrosis-related biomarkers and correlation with histological response in the FALCON 1 trial.
Brown EA; Minnich A; Sanyal AJ; Loomba R; Du S; Schwarz J; Ehman RL; Karsdal M; Leeming DJ; Cizza G; Charles ED
JHEP Rep; 2023 Apr; 5(4):100661. PubMed ID: 36866389
[TBL] [Abstract][Full Text] [Related]
4. Efruxifermin in non-alcoholic steatohepatitis: a randomized, double-blind, placebo-controlled, phase 2a trial.
Harrison SA; Ruane PJ; Freilich BL; Neff G; Patil R; Behling CA; Hu C; Fong E; de Temple B; Tillman EJ; Rolph TP; Cheng A; Yale K
Nat Med; 2021 Jul; 27(7):1262-1271. PubMed ID: 34239138
[TBL] [Abstract][Full Text] [Related]
5. Safety and Efficacy of Efruxifermin in Combination With a GLP-1 Receptor Agonist in Patients With NASH/MASH and Type 2 Diabetes in a Randomized Phase 2 Study.
Harrison SA; Frias JP; Lucas KJ; Reiss G; Neff G; Bollepalli S; Su Y; Chan D; Tillman EJ; Moulton A; de Temple B; Zari A; Shringarpure R; Rolph T; Cheng A; Yale K
Clin Gastroenterol Hepatol; 2024 Mar; ():. PubMed ID: 38447814
[TBL] [Abstract][Full Text] [Related]
6. Safety, pharmacokinetics, and pharmacodynamics of pegozafermin in patients with non-alcoholic steatohepatitis: a randomised, double-blind, placebo-controlled, phase 1b/2a multiple-ascending-dose study.
Loomba R; Lawitz EJ; Frias JP; Ortiz-Lasanta G; Johansson L; Franey BB; Morrow L; Rosenstock M; Hartsfield CL; Chen CY; Tseng L; Charlton RW; Mansbach H; Margalit M
Lancet Gastroenterol Hepatol; 2023 Feb; 8(2):120-132. PubMed ID: 36521501
[TBL] [Abstract][Full Text] [Related]
7. Pegbelfermin in Patients With Nonalcoholic Steatohepatitis and Compensated Cirrhosis (FALCON 2): A Randomized Phase 2b Study.
Abdelmalek MF; Sanyal AJ; Nakajima A; Neuschwander-Tetri BA; Goodman ZD; Lawitz EJ; Harrison SA; Jacobson IM; Imajo K; Gunn N; Halegoua-DeMarzio D; Akahane T; Boone B; Yamaguchi M; Chatterjee A; Tirucherai GS; Shevell DE; Du S; Charles ED; Loomba R
Clin Gastroenterol Hepatol; 2024 Jan; 22(1):113-123.e9. PubMed ID: 37088458
[TBL] [Abstract][Full Text] [Related]
8. Non-invasive evaluation of response to obeticholic acid in patients with NASH: Results from the REGENERATE study.
Rinella ME; Dufour JF; Anstee QM; Goodman Z; Younossi Z; Harrison SA; Loomba R; Sanyal AJ; Bonacci M; Trylesinski A; Natha M; Shringarpure R; Granston T; Venugopal A; Ratziu V
J Hepatol; 2022 Mar; 76(3):536-548. PubMed ID: 34793868
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of PXL065 - deuterium-stabilized (R)-pioglitazone in patients with NASH: A phase II randomized placebo-controlled trial (DESTINY-1).
Harrison SA; Thang C; Bolze S; Dewitt S; Hallakou-Bozec S; Dubourg J; Bedossa P; Cusi K; Ratziu V; Grouin JM; Moller DE; Fouqueray P
J Hepatol; 2023 May; 78(5):914-925. PubMed ID: 36804402
[TBL] [Abstract][Full Text] [Related]
10. Insulin sensitizer MSDC-0602K in non-alcoholic steatohepatitis: A randomized, double-blind, placebo-controlled phase IIb study.
Harrison SA; Alkhouri N; Davison BA; Sanyal A; Edwards C; Colca JR; Lee BH; Loomba R; Cusi K; Kolterman O; Cotter G; Dittrich HC
J Hepatol; 2020 Apr; 72(4):613-626. PubMed ID: 31697972
[TBL] [Abstract][Full Text] [Related]
11. Selonsertib for patients with bridging fibrosis or compensated cirrhosis due to NASH: Results from randomized phase III STELLAR trials.
Harrison SA; Wong VW; Okanoue T; Bzowej N; Vuppalanchi R; Younes Z; Kohli A; Sarin S; Caldwell SH; Alkhouri N; Shiffman ML; Camargo M; Li G; Kersey K; Jia C; Zhu Y; Djedjos CS; Subramanian GM; Myers RP; Gunn N; Sheikh A; Anstee QM; Romero-Gomez M; Trauner M; Goodman Z; Lawitz EJ; Younossi Z; ;
J Hepatol; 2020 Jul; 73(1):26-39. PubMed ID: 32147362
[TBL] [Abstract][Full Text] [Related]
12. The FALCON program: Two phase 2b randomized, double-blind, placebo-controlled studies to assess the efficacy and safety of pegbelfermin in the treatment of patients with nonalcoholic steatohepatitis and bridging fibrosis or compensated cirrhosis.
Abdelmalek MF; Charles ED; Sanyal AJ; Harrison SA; Neuschwander-Tetri BA; Goodman Z; Ehman RA; Karsdal M; Nakajima A; Du S; Tirucherai GS; Klinger GH; Mora J; Yamaguchi M; Shevell DE; Loomba R
Contemp Clin Trials; 2021 May; 104():106335. PubMed ID: 33657443
[TBL] [Abstract][Full Text] [Related]
13. Pegbelfermin in Patients With Nonalcoholic Steatohepatitis and Stage 3 Fibrosis (FALCON 1): A Randomized Phase 2b Study.
Loomba R; Sanyal AJ; Nakajima A; Neuschwander-Tetri BA; Goodman ZD; Harrison SA; Lawitz EJ; Gunn N; Imajo K; Ravendhran N; Akahane T; Boone B; Yamaguchi M; Chatterjee A; Tirucherai GS; Shevell DE; Du S; Charles ED; Abdelmalek MF
Clin Gastroenterol Hepatol; 2024 Jan; 22(1):102-112.e9. PubMed ID: 37088457
[TBL] [Abstract][Full Text] [Related]
14. Combination Therapies Including Cilofexor and Firsocostat for Bridging Fibrosis and Cirrhosis Attributable to NASH.
Loomba R; Noureddin M; Kowdley KV; Kohli A; Sheikh A; Neff G; Bhandari BR; Gunn N; Caldwell SH; Goodman Z; Wapinski I; Resnick M; Beck AH; Ding D; Jia C; Chuang JC; Huss RS; Chung C; Subramanian GM; Myers RP; Patel K; Borg BB; Ghalib R; Kabler H; Poulos J; Younes Z; Elkhashab M; Hassanein T; Iyer R; Ruane P; Shiffman ML; Strasser S; Wong VW; Alkhouri N;
Hepatology; 2021 Feb; 73(2):625-643. PubMed ID: 33169409
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and Safety of Aldafermin, an Engineered FGF19 Analog, in a Randomized, Double-Blind, Placebo-Controlled Trial of Patients With Nonalcoholic Steatohepatitis.
Harrison SA; Neff G; Guy CD; Bashir MR; Paredes AH; Frias JP; Younes Z; Trotter JF; Gunn NT; Moussa SE; Kohli A; Nelson K; Gottwald M; Chang WCG; Yan AZ; DePaoli AM; Ling L; Lieu HD
Gastroenterology; 2021 Jan; 160(1):219-231.e1. PubMed ID: 32781086
[TBL] [Abstract][Full Text] [Related]
16. A randomized, double-blind, placebo-controlled trial of aldafermin in patients with NASH and compensated cirrhosis.
Rinella ME; Lieu HD; Kowdley KV; Goodman ZD; Alkhouri N; Lawitz E; Ratziu V; Abdelmalek MF; Wong VW; Younes ZH; Sheikh AM; Brannan D; Freilich B; Membreno F; Sinclair M; Melchor-Khan L; Sanyal AJ; Ling L; Harrison SA
Hepatology; 2024 Mar; 79(3):674-689. PubMed ID: 37732990
[TBL] [Abstract][Full Text] [Related]
17. Safety and efficacy of combination therapy with semaglutide, cilofexor and firsocostat in patients with non-alcoholic steatohepatitis: A randomised, open-label phase II trial.
Alkhouri N; Herring R; Kabler H; Kayali Z; Hassanein T; Kohli A; Huss RS; Zhu Y; Billin AN; Damgaard LH; Buchholtz K; Kjær MS; Balendran C; Myers RP; Loomba R; Noureddin M
J Hepatol; 2022 Sep; 77(3):607-618. PubMed ID: 35439567
[TBL] [Abstract][Full Text] [Related]
18. Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial.
Younossi ZM; Ratziu V; Loomba R; Rinella M; Anstee QM; Goodman Z; Bedossa P; Geier A; Beckebaum S; Newsome PN; Sheridan D; Sheikh MY; Trotter J; Knapple W; Lawitz E; Abdelmalek MF; Kowdley KV; Montano-Loza AJ; Boursier J; Mathurin P; Bugianesi E; Mazzella G; Olveira A; Cortez-Pinto H; Graupera I; Orr D; Gluud LL; Dufour JF; Shapiro D; Campagna J; Zaru L; MacConell L; Shringarpure R; Harrison S; Sanyal AJ;
Lancet; 2019 Dec; 394(10215):2184-2196. PubMed ID: 31813633
[TBL] [Abstract][Full Text] [Related]
19. Farnesoid X receptor agonist tropifexor attenuates cholestasis in a randomised trial in patients with primary biliary cholangitis.
Schramm C; Wedemeyer H; Mason A; Hirschfield GM; Levy C; Kowdley KV; Milkiewicz P; Janczewska E; Malova ES; Sanni J; Koo P; Chen J; Choudhury S; Klickstein LB; Badman MK; Jones D
JHEP Rep; 2022 Nov; 4(11):100544. PubMed ID: 36267872
[TBL] [Abstract][Full Text] [Related]
20. Potent suppression of hydrophobic bile acids by aldafermin, an FGF19 analogue, across metabolic and cholestatic liver diseases.
Sanyal AJ; Ling L; Beuers U; DePaoli AM; Lieu HD; Harrison SA; Hirschfield GM
JHEP Rep; 2021 Jun; 3(3):100255. PubMed ID: 33898959
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]